Real-world exposure to graphic warning labels on cigarette packages in US smokers: The CASA randomized trial protocol.

Graphic warning label Health warnings Plain packaging Randomized controlled trial Smoking Standardized packaging

Journal

Contemporary clinical trials
ISSN: 1559-2030
Titre abrégé: Contemp Clin Trials
Pays: United States
ID NLM: 101242342

Informations de publication

Date de publication:
11 2020
Historique:
received: 19 05 2020
revised: 11 09 2020
accepted: 14 09 2020
pubmed: 24 9 2020
medline: 25 9 2021
entrez: 23 9 2020
Statut: ppublish

Résumé

The US lags behind >120 countries in implementing graphic warning labels (GWLs) on cigarette packs. US courts prevented implementation of FDA's 2012 rule requiring GWLs citing the need for more evidence on effectiveness. After more research, in 2020, the FDA proposed a revised rule mandating GWLs. This trial will test how the introduction of GWLs influence cognitions and behavior in US smokers. To investigate the "real-world" impact of GWLs in US smokers, we are conducting a randomized trial involving a 3-month intervention and 8-month follow-up. The study recruited California smokers between September 2016 through December 2019 and randomly assigned them into 3 groups (1) Blank Pack devoid of any cigarette branding; (2) GWL Pack featuring 1 of 3 rotating images added to blank pack; or (3) their usual Standard US Pack. Throughout the 3-month intervention, participants purchased study-packaged cigarettes and reported daily cognitions and behavior through ecological momentary assessments. We will validate self-reported tobacco use with saliva cotinine concentrations following the 3-month intervention and 8-month follow-up. The trial enrolled 359 participants (average age 39 years; average cigarette consumption half a pack/day). The 3 study groups were balanced on age, gender, race-ethnicity, education and income (17% low income) as well as on smoking related variables. This 3-month real-world randomized trial will test the effect of repackaging cigarettes from standard US packs to GWL plain packs on smokers' perceptions of the risks of smoking, their perception of the appeal of their cigarettes, and on their smoking behavior.

Sections du résumé

BACKGROUND
The US lags behind >120 countries in implementing graphic warning labels (GWLs) on cigarette packs. US courts prevented implementation of FDA's 2012 rule requiring GWLs citing the need for more evidence on effectiveness. After more research, in 2020, the FDA proposed a revised rule mandating GWLs. This trial will test how the introduction of GWLs influence cognitions and behavior in US smokers.
METHOD
To investigate the "real-world" impact of GWLs in US smokers, we are conducting a randomized trial involving a 3-month intervention and 8-month follow-up. The study recruited California smokers between September 2016 through December 2019 and randomly assigned them into 3 groups (1) Blank Pack devoid of any cigarette branding; (2) GWL Pack featuring 1 of 3 rotating images added to blank pack; or (3) their usual Standard US Pack. Throughout the 3-month intervention, participants purchased study-packaged cigarettes and reported daily cognitions and behavior through ecological momentary assessments. We will validate self-reported tobacco use with saliva cotinine concentrations following the 3-month intervention and 8-month follow-up.
RESULTS
The trial enrolled 359 participants (average age 39 years; average cigarette consumption half a pack/day). The 3 study groups were balanced on age, gender, race-ethnicity, education and income (17% low income) as well as on smoking related variables.
CONCLUSIONS
This 3-month real-world randomized trial will test the effect of repackaging cigarettes from standard US packs to GWL plain packs on smokers' perceptions of the risks of smoking, their perception of the appeal of their cigarettes, and on their smoking behavior.

Identifiants

pubmed: 32966877
pii: S1551-7144(20)30230-5
doi: 10.1016/j.cct.2020.106152
pmc: PMC7502239
mid: NIHMS1632966
pii:
doi:

Types de publication

Clinical Trial Protocol Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

106152

Subventions

Organisme : NCI NIH HHS
ID : R01 CA190347
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA234539
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

Addict Behav. 2007 May;32(5):912-23
pubmed: 16875787
Tob Control. 2008 Dec;17(6):416-21
pubmed: 18827035
Nicotine Tob Res. 2013 Mar;15(3):708-17
pubmed: 22990228
JAMA Intern Med. 2016 Jul 1;176(7):905-12
pubmed: 27273839
Nicotine Tob Res. 2015 Jul;17(7):776-83
pubmed: 25239958
BMC Fam Pract. 2016 Jun 24;17:73
pubmed: 27342987
Psychol Addict Behav. 2016 Dec;30(8):887-894
pubmed: 27831717
Ann Behav Med. 2019 Mar 1;53(3):232-243
pubmed: 29850764
Tob Control. 1999 Autumn;8(3):261-5
pubmed: 10599569
PLoS One. 2015 Dec 16;10(12):e0142879
pubmed: 26672982
Health Qual Life Outcomes. 2018 Sep 21;16(1):192
pubmed: 30241527
BMC Med Res Methodol. 2007 Jul 03;7:30
pubmed: 17608932
Tob Control. 2002 Mar;11 Suppl 1:I73-80
pubmed: 11893817
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Tob Control. 2019 Aug;28(e1):e71-e76
pubmed: 30610081
Nicotine Tob Res. 2011 Oct;13(10):911-8
pubmed: 21622495
J Adolesc Health. 2010 Apr;46(4):385-92
pubmed: 20307829
Tob Control. 2015 Apr;24(Suppl 2):ii33-ii41
pubmed: 28407610
Tob Control. 2017 Jul;26(4):485-486
pubmed: 27343227
J Pers Soc Psychol. 1988 Jun;54(6):1063-70
pubmed: 3397865
Stat Med. 2008 Dec 30;27(30):6332-50
pubmed: 18937275
Tob Control. 2020 Apr 28;:
pubmed: 32345609
Eur J Public Health. 2009 Dec;19(6):631-7
pubmed: 19726589
Int J Methods Psychiatr Res. 2012 Jun;21(2):88-97
pubmed: 22351472
Br J Addict. 1991 Sep;86(9):1119-27
pubmed: 1932883
Tob Control. 2017 Mar;26(e1):e59-e60
pubmed: 27742918
Tob Control. 2016 May;25(3):341-54
pubmed: 25948713
Tob Control. 2018 Oct;27(e2):e118-e123
pubmed: 29255011
Am J Prev Med. 2011 Jun;40(6):674-82
pubmed: 21565661
Am Psychol. 1992 Sep;47(9):1102-14
pubmed: 1329589
Drug Alcohol Depend. 2003 Dec 11;72(3):279-86
pubmed: 14643945
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):1821-6
pubmed: 21245314
Addict Behav. 1983;8(4):429-32
pubmed: 6677085
Perspect Psychol Sci. 2011 Jan;6(1):3-5
pubmed: 26162106
Addiction. 2012 Jun;107(6):1159-67
pubmed: 22372966
Nicotine Tob Res. 2019 Jun 21;21(7):855-862
pubmed: 29444268
J Natl Cancer Inst. 1995 Oct 18;87(20):1538-45
pubmed: 7563188
Int J Environ Res Public Health. 2018 Feb 28;15(3):
pubmed: 29495581

Auteurs

John P Pierce (JP)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States; Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: jppierce@ucsd.edu.

David R Strong (DR)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States; Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: dstrong@ucsd.edu.

Matthew D Stone (MD)

Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: m3stone@ucsd.edu.

Adriana Villaseñor (A)

Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: adriana.villasenor@sdcounty.ca.gov.

Claudiu V Dimofte (CV)

Department of Marketing, San Diego State University, 5500 Campanile Dr, San Diego, CA 92182, United States. Electronic address: cdimofte@sdsu.edu.

Eric C Leas (EC)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States; Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: ecleas@ucsd.edu.

Jesica Oratowski (J)

Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: joratowski@ucsd.edu.

Elizabeth Brighton (E)

Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: ebrighton@ucsd.edu.

Samantha Hurst (S)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States. Electronic address: shurst@ucsd.edu.

Kimberley Pulvers (K)

Department of Psychology, Social and Behavioral Sciences Building, California State University, San Marcos 200 E Barham Dr, San Marcos, CA, 92096, United States. Electronic address: kpulvers@csusm.edu.

Sheila Kealey (S)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States.

Ruifeng Chen (R)

Division of Biostatistics, Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: ruc075@ucsd.edu.

Karen Messer (K)

Cancer Control Program, Moores Cancer Center, UC San Diego, 3855 Health Sciences Drive, La Jolla, CA 92093-0901, United States; Division of Biostatistics, Department of Family Medicine and Public Health, UC San Diego, 9500 Gilman Drive, La Jolla, CA 92093, United States. Electronic address: kmesser@ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH